Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ryzodeg Flextouch - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Ryzodeg Flextouch

Approved

STANDARD

Ryzodeg Flextouch

Novo Nordisk Production SAS🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 9de0912438b349f8
Company: Novo Nordisk Production SAS
Type: Standard

Approval Details

Approval Id: 9de0912438b349f8
Drug Approval Philippines Name: Ryzodeg Flextouch
Product Name: Ryzodeg Flextouch
Registration Number: BR-1433
Brand Name: Ryzodeg Flextouch
Generic Name: Insulin Degludec + Insulin Aspart
Dosage Form: Solution for Injection (SC)
Dosage Strength: 100 Units/mL (70% Insulin Degludec/30% Insulin Aspart)
Manufacturer: Novo Nordisk Production SAS
Importer: Novo Nordisk Pharmaceuticals (Philippines), Inc.
Distributor: Novo Nordisk Pharmaceuticals (Philippines), Inc.
Issuance Date: 25 November 2022
Expiry Date: 25 November 2027
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

9de0912438b349f8

Type

Standard

Back to Philippines FDA Approvals